Plasmodium Falciparum Malaria

Infectious Diseases
5
Pipeline Programs
3
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 7 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
6 programs
2
1
FMP2.1/AS02APhase 21 trial
MSP1Phase 11 trial
MVA-CSO VaccinePhase 1Vaccine1 trial
Artemisinin-resistant Malaria in CambodiaN/A1 trial
Malaria Transmission and Immunity in Highland KenyaN/A1 trial
+1 more programs
Active Trials
NCT01736319CompletedEst. Apr 2016
NCT00393757CompletedEst. Jan 2011
NCT00593398CompletedEst. Sep 2013
+3 more trials
Novartis
NovartisBASEL, Switzerland
1 program
1
KAE609Phase 11 trial
Active Trials
NCT02543086Terminated8Est. Sep 2015
QT
Q TherapeuticsUT - Salt Lake City
1 program
1
SJ733 Induced Blood Stage Malaria Challenge StudyPhase 11 trial
Active Trials
NCT02867059CompletedEst. Dec 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allergy TherapeuticsFMP2.1/AS02A
Allergy TherapeuticsMVA-CSO Vaccine
Q TherapeuticsSJ733 Induced Blood Stage Malaria Challenge Study
NovartisKAE609
Allergy TherapeuticsMSP1
Allergy TherapeuticsArtemisinin-resistant Malaria in Cambodia
Allergy TherapeuticsMalarial Immunity in Pregnant Cameroonian Women
Allergy TherapeuticsMalaria Transmission and Immunity in Highland Kenya

Clinical Trials (8)

Total enrollment: 408 patients across 8 trials

NCT00460525Allergy TherapeuticsFMP2.1/AS02A

Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali

Start: May 2007Est. completion: Jul 2009400 patients
Phase 2Completed
NCT00377494Allergy TherapeuticsMVA-CSO Vaccine

CS DNA MVA Trial in Mampong, Ghana

Est. completion: Jul 2008
Phase 1Withdrawn
NCT02867059Q TherapeuticsSJ733 Induced Blood Stage Malaria Challenge Study

SJ733 Induced Blood Stage Malaria Challenge Study

Start: Sep 2016Est. completion: Dec 2016
Phase 1Completed
NCT02543086NovartisKAE609

Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos

Start: Jul 2015Est. completion: Sep 20158 patients
Phase 1Terminated
NCT00340431Allergy TherapeuticsMSP1

Experimental Vaccine for Plasmodium Falciparum Malaria

Start: Jun 2004Est. completion: Feb 2008
Phase 1Completed
NCT01736319Allergy TherapeuticsArtemisinin-resistant Malaria in Cambodia

Artemisinin-resistant Malaria in Cambodia

Start: Jun 2012Est. completion: Apr 2016
N/ACompleted
NCT00593398Allergy TherapeuticsMalarial Immunity in Pregnant Cameroonian Women

Malarial Immunity in Pregnant Cameroonian Women

Start: Sep 2008Est. completion: Sep 2013
N/ACompleted
NCT00393757Allergy TherapeuticsMalaria Transmission and Immunity in Highland Kenya

Malaria Transmission and Immunity in Highland Kenya

Start: Oct 2006Est. completion: Jan 2011
N/ACompleted

Related Jobs in Infectious Diseases

Senior Associate Scientist (contract), Upstream Polysaccharide Process Development

VaxCyte
San Carlos, California, United States
6h ago
$56/hr

Senior Associate Scientist (contract), Polysaccharide Analytical Development

VaxCyte
San Carlos, California, United States
6h ago
$56/hr

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
10h ago
$179K - $237K/yr

First Line Sales Leader (Medan)

GSK
Indonesia - Sumatera Utara
23h ago

General Worker

GSK
Pakistan - Sindh - Karachi
23h ago

Vaccine Business Manager (Jakarta)

GSK
Indonesia - DKI Jakarta
23h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)